Physician profile
Nora Kurbaj
NPI 1831716976
$9,517.04
in general payments reported to CMS, 2019-2025
35 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,337 · 2022: $4,048 · 2023: $896 · 2024: $1,114 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109 · Education: $22.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,109.45 |
| Education | $22.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,801.68 | 2021-2023 | Interstim |
| Tolmar, INC. | $1,002.93 | 2023-2025 | Jatenzo |
| Antares Pharma, INC. | $795.79 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Axonics, INC. | $726.93 | 2021-2023 | Axonics |
| Astellas Pharma US INC | $682.27 | 2021-2023 | Myrbetriq |
| Teleflex LLC | $634.09 | 2021-2023 | Urolift |
| Endo Pharmaceuticals INC. | $609.84 | 2021-2023 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $335.39 | 2021-2023 | Erleada |
| Novo Nordisk INC | $329.99 | 2023-2025 | Wegovy, Ozempic, Saxenda |
| Endo USA, INC. | $312.59 | 2024-2025 | Aveed, Xiaflex |
| Alnylam Pharmaceuticals INC. | $250.39 | 2021-2025 | Amvuttra, Givlaari |
| Acerus Pharmaceuticals Corporation | $204.09 | 2021-2022 | |
| Amgen INC. | $181.92 | 2023-2025 | Repatha, Repatha |
| Abbvie INC. | $168.99 | 2021-2025 | |
| Urogen Pharma, INC. | $159.08 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $139.68 | 2021-2022 | |
| Pfizer INC. | $112.99 | 2021-2024 | |
| Halozyme INC | $110.46 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $108.55 | 2021-2022 | |
| Allergan, INC. | $87.67 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $86.24 | 2025 | Azmiro |
| Blue Earth Diagnostics | $83.09 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $74.18 | 2022 | |
| Myovant Sciences INC. | $73.45 | 2021-2022 | |
| Lilly USA, LLC | $71.95 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $66.78 | 2022-2023 | Keytruda |
| Urovant Sciences INC | $57.78 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $45.96 | 2023 | Orgovyx, Gemtesa |
| Heartflow, INC. | $42.51 | 2023-2025 | Ffrct |
| Coloplast Corp | $34.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $32.44 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2022 | |
| Baxter Healthcare | $24.93 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Medicomp INC | $22.18 | 2025 | Telepatch Cardiac Monitor |
| Otsuka America Pharmaceutical, INC. | $21.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Kurbaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.